Lazertinib Disease Interactions
There are 4 disease interactions with lazertinib.
Lazertinib (applies to lazertinib) ILD/pneumonitis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Interstitial Pneumonitis
Lazertinib, which is administered in combination with amivantamab, can cause interstitial lung disease (ILD)/pneumonitis. Patients should be monitored for worsening or new symptoms indicative of ILD/pneumonitis, such as dyspnea, cough or fever.
Lazertinib (applies to lazertinib) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Lazertinib has not been studied in patients with severe hepatic impairment (total bilirubin greater than 3 x upper limit of normal and any AST).
Lazertinib (applies to lazertinib) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Lazertinib has not been studied in patients with severe renal dysfunction or end-stage renal disease (eGFR less than 30 mL/min).
Lazertinib (applies to lazertinib) vision disturbances
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance
Lazertinib, which is administered in combination with amivantamab, can cause ocular toxicity, including keratitis. Patients should be monitored for new or worsening eye symptoms and referred promptly to an ophthalmologist.
Switch to professional interaction data
Lazertinib drug interactions
There are 376 drug interactions with lazertinib.
More about lazertinib
- lazertinib consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: EGFR inhibitors
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.